Vir Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Vir Biotechnology has a total shareholder equity of $1.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $257.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$914.47m |
| Equity | US$1.24b |
| Total liabilities | US$257.63m |
| Total assets | US$1.50b |
Recent financial health updates
Recent updates
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Nov 05Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
Nov 04
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Sep 08Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Financial Position Analysis
Short Term Liabilities: VIR's short term assets ($1.0B) exceed its short term liabilities ($117.2M).
Long Term Liabilities: VIR's short term assets ($1.0B) exceed its long term liabilities ($140.5M).
Debt to Equity History and Analysis
Debt Level: VIR is debt free.
Reducing Debt: VIR had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIR has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 0.3% each year.